SMARCB1型
非典型畸胎样横纹肌瘤
先证者
生殖系
基因检测
家族史
医学
脑瘤
髓母细胞瘤
遗传学
生物信息学
突变
生物
癌症研究
内科学
病理
基因
表观遗传学
染色质重塑
作者
Patrick R. Blackburn,Rose B. McGee,Roya Mostafavi,Andrew J. Carroll,Fady M. Mikhail,Gregory T. Armstrong,Larissa V. Furtado,Jason Chiang,David A. Wheeler,Steven S. Carey,Kim E. Nichols,Santhosh A. Upadhyaya
摘要
Abstract Rhabdoid Tumor Predisposition Syndrome 1 (RTPS1) confers an increased risk of developing rhabdoid tumors and is caused by germline mutations in SMARCB1 . RTPS1 should be evaluated in all individuals with rhabdoid tumor and is more likely in those with a young age at presentation (occasionally congenital presentation), multiple primary tumors, or a family history of rhabdoid tumor or RTPS1. Proband genetic testing is the standard method for diagnosing RTPS1. Most known RTPS1‐related SMARCB1 gene mutations are copy number variants (CNVs) or single nucleotide variants/indels, but structural variant analysis (SVA) is not usually included in the molecular evaluation. Here, we report two children with RTPS1 presenting with atypical teratoid/rhabdoid tumor (ATRT) who had constitutional testing showing balanced chromosome translocations involving SMARCB1 . Patient 1 is a 23‐year‐old female diagnosed with pineal region ATRT at 7 months who was found to have a de novo , constitutional t(16;22)(p13.3;q11.2). Patient 2 is a 24‐month‐old male diagnosed with a posterior fossa ATRT at 14 months, with subsequent testing showing a constitutional t(5;22)(q14.1;q11.23). These structural rearrangements have not been previously reported in RTPS1. While rare, these cases suggest that structural variants should be considered in the evaluation of children with rhabdoid tumors to provide more accurate genetic counseling on the risks of developing tumors, the need for surveillance, and the risks of passing the disorder on to future children. Further research is needed to understand the prevalence, clinical features, and tumor risks associated with RTPS1‐related constitutional balanced translocations.
科研通智能强力驱动
Strongly Powered by AbleSci AI